Irbesartan/propagermanium

Drug Profile

Irbesartan/propagermanium

Alternative Names: DMX-200

Latest Information Update: 06 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dimerix Bioscience
  • Class Biphenyl compounds; Organometallic compounds; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Renal failure

Most Recent Events

  • 06 Apr 2017 Irbesartan/propagermanium is still in phase II trials for Renal failure in Australia (PO)
  • 14 Sep 2015 Phase-II clinical trials in Renal failure in Australia (PO)
  • 29 Dec 2014 Irbesartan/propagermanium is available for licensing as of 01 Jun 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top